St George's Hospital
St George's Hospital
London, United Kingdom15 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | cancer, neoplasm | Active, not recruiting | Phase 3 | 2026-10-08 | NCT03148418 | |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07210723 | |
| RTX001 Autologous Engineered Macrophages for Liver Cirrhosis | Brain Diseases, Metabolic, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Jaundice, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, brain disorder, central nervous system disorder, chronic liver failure, cirrhosis of liver, hepatic encephalopathy, hyperbilirubinemia, liver disorder, liver failure, metabolic disease, nervous system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT06823713 | |
| A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy (DCM) | Recruiting | Phase 3 | 2026-10-02 | NCT07771465 | |
| A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | interstitial lung disease, lung disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06806592 | |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06531824 | |
| An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder | Recruiting | Not stated | 2026-09-25 | NCT04750798 | |
| Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk | cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2026-07-28 | NCT07067658 | |
| The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Recruiting | Not applicable | 2026-07-21 | NCT04204915 | |
| The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER) | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-05-18 | NCT03171311 | |
| MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 3 | 2026-04-28 | NCT04116502 | |
| Study in Patients With Decompensated Liver Cirrhosis | Brain Diseases, Metabolic, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, central nervous system disorder, chronic liver failure, cirrhosis of liver, hepatic encephalopathy, liver disorder, liver failure, metabolic disease, nervous system disorder | Active, not recruiting | Not stated | 2026-01-29 | NCT06380335 | |
| Speech Performance and Clinic Efficiency With Remote Care Compared With Standard of Care in Adults With a Cochlear Implant in the First 12 Months Post-activation | Ear Diseases, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, nervous system disorder, otorhinolaryngologic disease | Active, not recruiting | Not applicable | 2026-01-16 | NCT05552118 | |
| Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) | CNS demyelinating autoimmune disease, Charcot-Marie-Tooth disease type 1F, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Recruiting | Phase 2 | 2026-01-07 | NCT05418010 | |
| Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2024-12-06 | NCT02315716 |